[en] Genotoxic agents, that are used in cancer therapy, elicit the reprogramming of the transcriptome of cancer cells. These changes reflect the cellular response to stress and underlie some of the mechanisms leading to drug resistance. Here, we profiled genome-wide changes in pre-mRNA splicing induced by cisplatin in breast cancer cells. Among the set of cisplatin-induced alternative splicing events we focused on COASY, a gene encoding a mitochondrial enzyme involved in coenzyme A biosynthesis. Treatment with cisplatin induces the production of a short isoform of COASY lacking exons 4 and 5, whose depletion impedes mitochondrial function and decreases sensitivity to cisplatin. We identified RBM39 as a major effector of the cisplatin-induced effect on COASY splicing. RBM39 also controls a genome-wide set of alternative splicing events partially overlapping with the cisplatin-mediated ones. Unexpectedly, inactivation of RBM39 in response to cisplatin involves its interaction with the AP-1 family transcription factor c-Jun that prevents RBM39 binding to pre-mRNA. Our findings therefore uncover a novel cisplatin-induced interaction between a splicing regulator and a transcription factor that has a global impact on alternative splicing and contributes to drug resistance.
Chakrama, Fatima ✱; Université de Liège - ULiège > GIGA > GIGA I3 - Virology and Immunology
O'Grady, Tina ; Université de Liège - ULiège > GIGA > GIGA Molecular Biology of Diseases - Gene Expression & Cancer
Peulen, Olivier ; Université de Liège - ULiège > GIGA > GIGA Cancer - Metastases Research Laboratory
Rademaker, Gilles ; Université de Liège - ULiège > GIGA > GIGA Cancer - Metastases Research Laboratory
Deward, Adeline ; Université de Liège - ULiège > Département de gestion vétérinaire des Ressources Animales (DRA) > Génomique animale
Chabot, Benoit ; Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences. Université de Sherbrooke, Sherbrooke, Québec, Canada
Piette, Jacques ; Université de Liège - ULiège > GIGA > GIGA I3 - Virology and Immunology
Colige, Alain ; Université de Liège - ULiège > GIGA > GIGA Cancer - Connective Tissue Biology
Lambert, Charles ; Université de Liège - ULiège > GIGA > GIGA Cancer - Connective Tissue Biology
Dequiedt, Franck ✱; Université de Liège - ULiège > Département des sciences de la vie > Génétique et biologie moléculaires animales
Habraken, Yvette ✱; Université de Liège - ULiège > Département des sciences de la vie
✱ These authors have contributed equally to this work.
Language :
English
Title :
The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress.
Alternative titles :
[fr] Le facteur de transcription c-Jun inhibe RBM39 pour reprogrammer l'épissage des ARNs pré-messager lors d'un stress génotoxique
ULiège - Université de Liège [BE] CAC - Centre anticancéreux près l'Université de Liège asbl [BE] Fonds Léon Fredericq [BE] BELSPO - Belgian Science Policy Office [BE] Belgian Foundation Against Cancer [BE] CIHR - Canadian Institutes of Health Research [CA] Télévie [BE] F.R.S.-FNRS - Fonds de la Recherche Scientifique [BE]
Funding number :
BelPD
Funding text :
Fonds Sectoriels de l'Université de Liège; Actions de Recherche Concertée
Commentary :
The authors wish it to be known that, in their opinion, the first two authors and last two authors should be regarded as Joint First and Joint Last Authors,respectively
Hegele,A., Kamburov,A., Grossmann,A., Sourlis,C., Wowro,S., Weimann,M., Will,C.L., Pena,V., Lührmann,R. and Stelzl,U. (2012) Dynamic protein-protein interaction wiring of the human spliceosome. Mol. Cell, 45, 567–580.
Ule,J. and Blencowe,B.J. (2019) Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol. Cell, 76, 329–345.
Fu,X.-D. and Ares,M. (2014) Context-dependent control of alternative splicing by RNA-binding proteins. Nat. Rev. Genet., 15, 689–701.
Han,H., Braunschweig,U., Gonatopoulos-Pournatzis,T., Weatheritt,R.J., Hirsch,C.L., Ha,K.C.H., Radovani,E., Nabeel-Shah,S., Sterne-Weiler,T., Wang,J. et al. (2017) Multilayered control of alternative splicing regulatory networks by transcription factors. Mol. Cell, 65, 539–553.
Tejedor,J.R., Papasaikas,P. and Valcárcel,J. (2015) Genome-wide identification of fas/cd95 alternative splicing regulators reveals links with iron homeostasis. Mol. Cell, 57, 23–38.
Gonatopoulos-Pournatzis,T., Wu,M., Braunschweig,U., Roth,J., Han,H., Best,A.J., Raj,B., Aregger,M., O’Hanlon,D., Ellis,J.D. et al. (2018) Genome-wide CRISPR-Cas9 interrogation of splicing networks reveals a mechanism for recognition of autism-misregulated neuronal microexons. Mol. Cell, 72, 510–524.
Rambout,X., Dequiedt,F. and Maquat,L.E. (2018) Beyond transcription: roles of transcription factors in pre-mRNA splicing. Chem. Rev., 118, 4339–4364.
Saulnier,O., Guedri-Idjouadiene,K., Aynaud,M.-M., Chakraborty,A., Bruyr,J., Pineau,J., O’Grady,T., Mirabeau,O., Grossetête,S., Galvan,B. et al. (2021) ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion. Nucleic Acids Res., 49, 5038–5056.
Boumpas,P., Merabet,S. and Carnesecchi,J. (2022) Integrating transcription and splicing into cell fate: transcription factors on the block. Wiley Interdiscip. Rev. RNA, e1752.
Mai,S., Qu,X., Li,P., Ma,Q., Cao,C. and Liu,X. (2016) Global regulation of alternative RNA splicing by the SR-rich protein RBM39. Biochim. Biophys. Acta, 1859, 1014–1024.
Wang,E., Lu,S.X., Pastore,A., Chen,X., Imig,J., Chun-Wei Lee,S., Hockemeyer,K., Ghebrechristos,Y.E., Yoshimi,A., Inoue,D. et al. (2019) Targeting an RNA-Binding protein network in acute myeloid leukemia. Cancer Cell, 35, 369–384.
Královicová,J., Ševcíková,I., Stejskalová,E., Obuca,M., Hiller,M., Stanek,D. and Vorechovský,I. (2018) PUF60-activated exons uncover altered 3’ splice-site selection by germline missense mutations in a single RRM. Nucleic Acids Res., 46, 6166–6187.
Han,T., Goralski,M., Gaskill,N., Capota,E., Kim,J., Ting,T.C., Xie,Y., Williams,N.S. and Nijhawan,D. (2017) Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science, 356, eaal3755.
Uehara,T., Minoshima,Y., Sagane,K., Sugi,N.H., Mitsuhashi,K.O., Yamamoto,N., Kamiyama,H., Takahashi,K., Kotake,Y., Uesugi,M. et al. (2017) Selective degradation of splicing factor CAPERα by anticancer sulfonamides. Nat. Chem. Biol., 13, 675–680.
Xu,C., Chen,X., Zhang,X., Zhao,D., Dou,Z., Xie,X., Li,H., Yang,H., Li,Q., Zhang,H. et al. (2021) RNA-binding protein 39: a promising therapeutic target for cancer. Cell Death Discov., 7, 214.
Jung,D.-J., Na,S.-Y., Na,D.S. and Lee,J.W. (2002) Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J. Biol. Chem., 277, 1229–1234.
Dutta,J., Fan,G. and Gélinas,C. (2008) CAPERα is a novel rel-tad-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kB oncoprotein v-Rel. J. Virol., 82, 10792–10802.
Dowhan,D.H., Hong,E.P., Auboeuf,D., Dennis,A.P., Wilson,M.M., Berget,S.M. and O’Malley,B.W. (2005) Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell, 17, 429–439.
Hess,J., Angel,P. and Schorpp-Kistner,M. (2004) AP-1 subunits: quarrel and harmony among siblings. J. Cell Sci., 117, 5965–5973.
Chinenov,Y. and Kerppola,T.K. (2001) Close encounters of many kinds: fos-jun interactions that mediate transcription regulatory specificity. Oncogene, 20, 2438–2452.
Dasari,S. and Tchounwou,P.B. (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol., 740, 364–378.
Kleih,M., Böpple,K., Dong,M., Gaißler,A., Heine,S., Olayioye,M.A., Aulitzky,W.E. and Essmann,F. (2019) Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death. Dis., 10, 851.
Vasan,N., Baselga,J. and Hyman,D.M. (2019) A view on drug resistance in cancer. Nature, 575, 299–309.
Cocetta,V., Ragazzi,E. and Montopoli,M. (2019) Mitochondrial involvement in cisplatin resistance. Int. J. Mol. Sci., 20, 3384.
Mitra,K., Wunder,C., Roysam,B., Lin,G. and Lippincott-Schwartz,J. (2009) A hyperfused mitochondrial state achieved at G1–S regulates cyclin e buildup and entry into s phase. Proc. Natl Acad. Sci. U.S.A., 106, 11960–11965.
Youle,R.J. and van der Bliek,A.M. (2012) Mitochondrial fission, fusion, and stress. Science, 337, 1062–1065.
Sancar,A., Lindsey-Boltz,L.A., Unsal-Kaçmaz,K. and Linn,S. (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem., 73, 39–85.
Sabatel,H., Pirlot,C., Piette,J. and Habraken,Y. (2011) Importance of PIKKs in NF-kB activation by genotoxic stress. Biochem. Pharmacol., 82, 1371–1383.
Boucas,J., Riabinska,A., Jokic,M., Herter-Sprie,G.S., Chen,S., Höpker,K. and Reinhardt,H.C. (2012) Posttranscriptional regulation of gene expression––adding another layer of complexity to the DNA damage response. Front. Genet., 3, 159.
Reinhardt,H.C., Cannell,I.G., Morandell,S. and Yaffe,M.B. (2011) Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response?Cell Cycle, 10, 23–27.
Tanaka,I., Chakraborty,A., Saulnier,O., Benoit-Pilven,C., Vacher,S., Labiod,D., Lam,E.W.F., Bièche,I., Delattre,O., Pouzoulet,F. et al. (2020) ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. Nucleic Acids Res., 48, 2676–2693.
Gabriel,M., Delforge,Y., Deward,A., Habraken,Y., Hennuy,B., Piette,J., Klinck,R., Chabot,B., Colige,A. and Lambert,C. (2015) Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis. BMC Cancer, 15, 227.
Shkreta,L. and Chabot,B. (2015) The RNA splicing response to DNA damage. Biomolecules, 5, 2935.
Dutertre,M., Lambert,S., Carreira,A., Amor-Guéret,M. and Vagner,S. (2014) DNA damage: RNA-binding proteins protect from near and far. Trends Biochem. Sci, 39, 141–149.
Mikolaskova,B., Jurcik,M., Cipakova,I., Kretova,M., Chovanec,M. and Cipak,L. (2018) Maintenance of genome stability: the unifying role of interconnections between the DNA damage response and RNA-processing pathways. Curr. Genet., 64, 971–983.
Zhyvoloup,A., Nemazanyy,I., Babich,A., Panasyuk,G., Pobigailo,N., Vudmaska,M., Naidenov,V., Kukharenko,O., Palchevskii,S., Savinska,L. et al. (2002) Molecular cloning of CoA synthase THE MISSING LINK IN CoA BIOSYNTHESIS. J. Biol. Chem., 277, 22107–22110.
Dusi,S., Valletta,L., Haack,T.B., Tsuchiya,Y., Venco,P., Pasqualato,S., Goffrini,P., Tigano,M., Demchenko,N., Wieland,T. et al. (2014) Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am. J. Hum. Genet., 94, 11–22.
Di Meo,I., Cavestro,C., Pedretti,S., Fu,T., Ligorio,S., Manocchio,A., Lavermicocca,L., Santambrogio,P., Ripamonti,M., Levi,S. et al. (2020) Neuronal ablation of CoA synthase causes motor deficits, iron dyshomeostasis, and mitochondrial dysfunctions in a CoPAN mouse model. Int. J. Mol. Sci., 21, E9707.
Breus,O., Panasyuk,G., Gout,I.T., Filonenko,V. and Nemazanyy,I. (2009) CoA synthase is in complex with p85αPI3K and affects PI3K signaling pathway. Biochem. Biophys. Res. Commun., 385, 581–585.
Ferrandon,S., DeVecchio,J., Duraes,L., Chouhan,H., Karagkounis,G., Davenport,J., Orloff,M., Liska,D. and Kalady,M.F. (2020) CoA synthase (COASY) mediates radiation resistance via PI3K signaling in rectal cancer. Cancer Res., 80, 334–346.
Lin,C.-C., Kitagawa,M., Tang,X., Hou,M.-H., Wu,J., Qu,D.C., Srinivas,V., Liu,X., Thompson,J.W., Mathey-Prevot,B. et al. (2018) CoA synthase regulates mitotic fidelity via CBP-mediated acetylation. Nat. Commun., 9, 1039.
Patro,R., Duggal,G., Love,M.I., Irizarry,R.A. and Kingsford,C. (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods, 14, 417–419.
Soneson,C., Love,M.I. and Robinson,M.D. (2015) Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res, 4, 1521.
Love,M.I., Huber,W. and Anders,S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 550.
Shen,S., Park,J.W., Lu,Z., Lin,L., Henry,M.D., Wu,Y.N., Zhou,Q. and Xing,Y. (2014) rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl. Acad. Sci. U.S.A., 111, E5593–E5601.
Huang,D.W., Sherman,B.T. and Lempicki,R.A. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44–57.
Subramanian,A., Tamayo,P., Mootha,V.K., Mukherjee,S., Ebert,B.L., Gillette,M.A., Paulovich,A., Pomeroy,S.L., Golub,T.R., Lander,E.S. et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A., 102, 15545–15550.
Wickham,H., François,R., Henry,L. and Müller,K. (2020) A Grammar of Data Manipulation (R package dplyr version 1.0.2).
Walther,P. and Ziegler,A. (2002) Freeze substitution of high-pressure frozen samples: the visibility of biological membranes is improved when the substitution medium contains water. J. Microsc., 208, 3–10.
Rademaker,G., Hennequière,V., Brohée,L., Nokin,M.-J., Lovinfosse,P., Durieux,F., Gofflot,S., Bellier,J., Costanza,B., Herfs,M. et al. (2018) Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness. Oncogene, 37, 4398–4412.
Yde,C.W. and Issinger,O.-G. (2006) Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of bcl-2 and cyclin d1. Int. J. Oncol., 29, 1397–1404.
Patel,T.H., Norman,L., Chang,S., Abedi,S., Liu,C., Chwa,M., Atilano,S.R., Thaker,K., Lu,S., Jazwinski,S.M. et al. (2019) European mtDNA variants are associated with differential responses to cisplatin, an anticancer drug: implications for drug resistance and side effects. Front. Oncol., 9, 640.
De Luca,A., Parker,L.J., Ang,W.H., Rodolfo,C., Gabbarini,V., Hancock,N.C., Palone,F., Mazzetti,A.P., Menin,L., Morton,C.J. et al. (2019) A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1. Proc. Natl. Acad. Sci. U.S.A., 116, 13943–13951.
Zamponi,N., Zamponi,E., Cannas,S.A., Billoni,O.V., Helguera,P.R. and Chialvo,D.R. (2018) Mitochondrial network complexity emerges from fission/fusion dynamics. Sci. Rep., 8, 363.
Kong,B., Wang,Q., Fung,E., Xue,K. and Tsang,B.K. (2014) p53 is required for Cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase oma1 in gynecologic cancers*. J. Biol. Chem., 289, 27134–27145.
Westermann,B. (2012) Bioenergetic role of mitochondrial fusion and fission. Biochim. Biophys. Acta Bioenerg., 1817, 1833–1838.
Marullo,R., Werner,E., Degtyareva,N., Moore,B., Altavilla,G., Ramalingam,S.S. and Doetsch,P.W. (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One, 8, e81162.
Venables,J.P., Brosseau,J.-P., Gadea,G., Klinck,R., Prinos,P., Beaulieu,J.-F., Lapointe,E., Durand,M., Thibault,P., Tremblay,K. et al. (2013) RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol. Cell. Biol., 33, 396–405.
Liu,J., Zhai,R., Zhao,J., Kong,F., Wang,J., Jiang,W., Xin,Q., Xue,X. and Luan,Y. (2018) Programmed cell death 4 overexpression enhances sensitivity to cisplatin via the JNK/c-Jun signaling pathway in bladder cancer. Int. J. Oncol., 52, 1633–1642.
Tsai,T.-F., Lin,J.-F., Lin,Y.-C., Chou,K.-Y., Chen,H.-E., Ho,C.-Y., Chen,P.-C. and Hwang,T.I.-S. (2019) Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. Biosci. Rep., 39, BSR20190362.
Jiang,Y., Jiang,J., Jia,H., Qiao,Z. and Zhang,J. (2018) Recovery of miR-139-5p in ovarian cancer reverses cisplatin resistance by targeting C-Jun. Cell. Physiol. Biochem., 51, 129–141.
Xia,Y., Yang,W., Bu,W., Ji,H., Zhao,X., Zheng,Y., Lin,X., Li,Y. and Lu,Z. (2013) Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells. J. Biol. Chem., 288, 19321–19329.
Dunn,C., Wiltshire,C., MacLaren,A. and Gillespie,D.A.F. (2002) Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. Cell Signal, 14, 585–593.
Jiang,C., Xuan,Z., Zhao,F. and Zhang,M.Q. (2007) TRED: a transcriptional regulatory element database, new entries and other development. Nucleic Acids Res., 35, D137–D140.
Han,H., Cho,J.-W., Lee,S., Yun,A., Kim,H., Bae,D., Yang,S., Kim,C.Y., Lee,M., Kim,E. et al. (2018) TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Res., 46, D380–D386.
Hayakawa,J., Mittal,S., Wang,Y., Korkmaz,K.S., Adamson,E., English,C., Omichi,M., McClelland,M. and Mercola,D. (2004) Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol. Cell, 16, 521–535.
Hafner,A., Bulyk,M.L., Jambhekar,A. and Lahav,G. (2019) The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell Biol., 20, 199–210.
Habraken,Y. and Piette,J. (2006) NF-kappaB activation by double-strand breaks. Biochem. Pharmacol., 72, 1132–1141.
Shiloh,Y. and Ziv,Y. (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol., 14, 197–210.
Roos,W.P., Thomas,A.D. and Kaina,B. (2016) DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer, 16, 20–33.
Harper,J.W. and Elledge,S.J. (2007) The DNA damage response: ten years after. Mol. Cell, 28, 739–745.
Anufrieva,K.S., Shender,V.O., Arapidi,G.P., Pavlyukov,M.S., Shakhparonov,M.I., Shnaider,P.V., Butenko,I.O., Lagarkova,M.A. and Govorun,V.M. (2018) Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells. Genome Med, 10, 49.
Shkreta,L., Toutant,J., Durand,M., Manley,J.L. and Chabot,B. (2016) SRSF10 connects DNA damage to the alternative splicing of transcripts encoding apoptosis, cell-cycle control, and DNA repair factors. Cell Rep., 17, 1990–2003.
Solier,S., Barb,J., Zeeberg,B.R., Varma,S., Ryan,M.C., Kohn,K.W., Weinstein,J.N., Munson,P.J. and Pommier,Y. (2010) Genome-wide analysis of novel splice variants induced by topoisomerase i poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res., 70, 8055–8065.
CeccatelliBerti,C., Dallabona,C., Lazzaretti,M., Dusi,S., Tosi,E., Tiranti,V. and Goffrini,P. (2015) Modeling human coenzyme a synthase mutation in yeast reveals altered mitochondrial function, lipid content and iron metabolism. Microb. Cell, 2, 126–135.
Kotzbauer,P.T., Truax,A.C., Trojanowski,J.Q. and Lee,V.M.-Y. (2005) Altered neuronal mitochondrial coenzyme a synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J. Neurosci., 25, 689–698.
Martins,N.M., Santos,N.a.G., Curti,C., Bianchi,M.L.P. and Santos,A.C. (2008) Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J. Appl. Toxicol., 28, 337–344.
Santandreu,F.M., Roca,P. and Oliver,J. (2010) Uncoupling protein-2 knockdown mediates the cytotoxic effects of cisplatin. Free Radic. Biol Med, 49, 658–666.
Sheng,J., Shen,L., Sun,L., Zhang,X., Cui,R. and Wang,L. (2019) Inhibition of PI3K/mTOR increased the sensitivity of hepatocellular carcinoma cells to cisplatin via interference with mitochondrial-lysosomal crosstalk. Cell Prolif., 52, e12609.
Luo,L., Xiong,Y., Jiang,N., Zhu,X., Wang,Y., Lv,Y. and Xie,Y. (2021) VDAC1 as a target in cisplatin anti-tumor activity through promoting mitochondria fusion. Biochem. Biophys. Res. Commun., 560, 52–58.
Cloutier,A., Shkreta,L., Toutant,J., Durand,M., Thibault,P. and Chabot,B. (2018) hnRNP A1/A2 and sam68 collaborate with SRSF10 to control the alternative splicing response to oxaliplatin-mediated DNA damage. Sci. Rep., 8, 2206.
Xu,Y., Nijhuis,A. and Keun,H.C. (2022) RNA-binding motif protein 39 (RBM39): an emerging cancer target. Br. J. Pharmacol., 179, 2795–2812.
Tari,M., Manceau,V., de Matha Salone,J., Kobayashi,A., Pastré,D. and Maucuer,A. (2019) U2AF65 assemblies drive sequence-specific splice site recognition. EMBO Rep., 20, e47604.
Stepanyuk,G.A., Serrano,P., Peralta,E., Farr,C.L., Axelrod,H.L., Geralt,M., Das,D., Chiu,H.-J., Jaroszewski,L., Deacon,A.M. et al. (2016) UHM–ULM interactions in the RBM39–U2AF65 splicing-factor complex. Acta Crystallogr. D Struct. Biol., 72, 497–511.
Campbell,M.C., Pontiggia,L., Russell,A.Y., Schwarting,R., Camacho,J., Jasmin,J.-F. and Mercier,I. (2018) CAPER as a therapeutic target for triple negative breast cancer. OncoTargets Ther., 9, 30340–30354.
Mercier,I., Gonzales,D.M., Quann,K., Pestell,T.G., Molchansky,A., Sotgia,F., Hulit,J., Gandara,R., Wang,C., Pestell,R.G. et al. (2014) CAPER, a novel regulator of human breast cancer progression. Cell Cycle, 13, 1256–1264.
Song,Y., Guo,Y., Li,X., Sun,R., Zhu,M., Shi,J., Tan,Z., Zhang,L. and Huang,J. (2021) RBM39 alters phosphorylation of c-Jun and binds to viral RNA to promote PRRSV proliferation. Front. Immunol., 12, 1681.
Chilewski,S.D., Bhosale,D., Dees,S., Hutchinson,I., Trimble,R., Pontiggia,L., Mercier,I. and Jasmin,J.-F. (2020) Development of CAPER peptides for the treatment of triple negative breast cancer. Cell Cycle, 19, 432–447.
Braunschweig,U., Gueroussov,S., Plocik,A.M., Graveley,B.R. and Blencowe,B.J. (2013) Dynamic integration of splicing within gene regulatory pathways. Cell, 152, 1252–1269.
Carnesecchi,J., Boumpas,P., van Nierop,Y, Sanchez,P., Domsch,K., Pinto,H.D., Borges Pinto,P. and Lohmann,I. (2022) The hox transcription factor ultrabithorax binds RNA and regulates co-transcriptional splicing through an interplay with RNA polymerase iI. Nucleic Acids Res., 50, 763–783.
Kalkat,M., Resetca,D., Lourenco,C., Chan,P.-K., Wei,Y., Shiah,Y.-J., Vitkin,N., Tong,Y., Sunnerhagen,M., Done,S.J. et al. (2018) MYC protein interactome profiling reveals functionally distinct regions that cooperate to drive tumorigenesis. Mol. Cell, 72, 836–848.
Liu,J., Guan,D., Dong,M., Yang,J., Wei,H., Liang,Q., Song,L., Xu,L., Bai,J., Liu,C. et al. (2020) UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nat. Cell Biol., 22, 1056–1063.
